EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?

Elisa Brochwitz, Ivonne Nel, Anne Eckardt, Laura Weydandt iD, Anne Kathrin Höhn, Karsten Winter, Bahriye Aktas iD

International Journal of Molecular Sciences · 28.05.2026 · 27 (11) · 4875

DOI: 10.3390/ijms27114875 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.05.2026. Verfasst von Elisa Brochwitz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Medical Center, University of Leipzig, 04103 Leipzig, Germany. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Uterine Cervical Neoplasms, Epithelial-Mesenchymal Transition. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite effective primary treatment, approximately 20% of cervical cancer patients experience recurrence, which may be driven by early hematogenous dissemination. While circulating (CTCs) and disseminated tumor cells (DTCs) are established prognostic markers in breast cancer, their role in cervical cancer remains poorly defined. Current detection methods rely predominantly on cytokeratin (CK) expression, but epithelial–mesenchymal transition (EMT) may lead to CK downregulation, potentially compromising detection sensitivity. We analyzed bone marrow (n = 43) and blood samples (collected pre-surgically and at follow-up) from cervical cancer patients. DTCs and CTCs were detected using a standardized CK based immunocytochemical assay. A multi-parameter immunofluorescence (IF) approach was employed to simultaneously assess CK, vimentin (Vim), p16, PD-L1 and VEGF on DTCs. Marker expression profiles were compared with matched tumor tissue and correlated with clinical and pathological parameters. CTCs were detected in 16% (7/43) of pre-surgical blood samples. DTC positivity increased from 56% (24/43) using CK based detection to 74% (32/43) when assessed via multi-parameter IF. A total of 248 DTCs were identified (median: 7 per patient). The most prevalent DTC phenotype was Vim+ (54%), followed by CK+ (12%), Vim+/VEGF+/p16+ (7%), and CK+/Vim+ (4%). Significant correlations were observed between p16 and VEGF (r = 0.631, p < 0.001) and between PD-L1 (r = 0.323, p < 0.001). Discordance between DTCs and tumor tissue reached 43–64%, primarily attributable to PD-L1 gain in DTCs. Over 70% of DTCs lacked CK, with majority exhibiting vimentin positivity, indicative of a mesenchymal phenotype. Vim+ and VEGF+ DTCs were associated with disease recurrence, suggesting their prognostic value. These findings underscore the limitations of relying solely on CK for DTC detection and highlight the potential of EMT and immune-related markers as novel biomarkers in cervical cancer. Further validation in larger, prospective cohorts is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Cells, CirculatingUterine Cervical NeoplasmsEpithelial-Mesenchymal TransitionHumansFemaleBiomarkers, TumorVimentinMiddle AgedVascular Endothelial Growth Factor AKeratinsAdultAgedB7-H1 AntigenPrognosisCyclin-Dependent Kinase Inhibitor p16

Stichwörter der Autor:innen

PD-L1VEGFVimentincervical cancercirculating tumor cells (CTCs)cytokeratindisseminated tumor cells (DTCs)epithelial–mesenchymal transition (EMT)p16phenotype

Substanzen

Biomarkers, TumorVimentinVascular Endothelial Growth Factor AKeratinsB7-H1 AntigenCyclin-Dependent Kinase Inhibitor p16CD274 protein, human

Autor:innen und Institutionen

  • Department of Gynecology, Medical Center, University of Leipzig, 04103 Leipzig, Germany.
  • Department of Pathology, Medical Center, University of Leipzig, 04103 Leipzig, Germany.
  • Institute of Anatomy, Medical Faculty, Leipzig University, 04103 Leipzig, Germany.

ORCID-Profile: Laura Weydandt, Bahriye Aktas

Zitieren

APA

Brochwitz, E., Nel, I., Eckardt, A., Weydandt, L., Höhn, A. K., Winter, K., & Aktas, B. (2026). Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?. International Journal of Molecular Sciences, 27(11), 4875. https://doi.org/10.3390/ijms27114875

Vancouver

Brochwitz E, Nel I, Eckardt A, Weydandt L, Höhn AK, Winter K, et al. Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?. International Journal of Molecular Sciences. 2026;27(11):4875. doi:10.3390/ijms27114875

BibTeX
@article{Brochwitz2026,
  author = {Brochwitz, Elisa and Nel, Ivonne and Eckardt, Anne and Weydandt, Laura and Höhn, Anne Kathrin and Winter, Karsten and Aktas, Bahriye},
  title = {Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {11},
  pages = {4875},
  doi = {10.3390/ijms27114875}
}
Kostenlos starten →